Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized intralesional L19IL2, L19TNF, or combination study in locally advanced basal cell carcinoma
2025-523229-16-00Phase 2Authorised
- Sponsor
- Philogen
- Start
- Apr 2026
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised trial of darleukin and onfekafusp alfa in basal cell carcinoma (BCC) (3 arms), sponsored by Philogen. Primary endpoint: Primary efficacy objective. Planned start Apr 2026; status: authorised.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2025-523229-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523229-16-00.